TG Therapeutics, Inc. (TGTX) Fair Value 2026

TGTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.1 /10

32 fundamental signals · 7 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-28, TG Therapeutics, Inc. (TGTX) trades at $53.93, versus a $11.89 median fair value across its 7 active models — 77.9% below the current price. QOC: 8.1/10. Value Trap Risk: 36/100 (LOW). 7/13 models active. Within that set, the Bayesian DCF component alone returns $11.89.

Key Facts

Ticker
TGTX
Price
$53.93
Quality Score
8.1/10
Value Trap Risk
36/100
Models Active
7/13
Last Updated
Strength: Quality Score of 8.1/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is TG Therapeutics, Inc. (TGTX) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, TG Therapeutics, Inc. (TGTX) appears overvalued as of : the median of 7 independent fair value estimates is $11.89, 77.9% below the current price of $53.93. Estimates range from $4.12 to $18.26. TGTX scores 8.1/10 on fundamental quality and 36/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. TGTX’s -77.9% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy TG Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give TGTX?

7 Intrinsic Value Models vs. Current Price ($53.93)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $11.89 -77.9%
Ensemble · Low Conviction
 $12.34 -77.1%
Scenario · High Conviction
 $4.12 -92.4%
Unlock the Full Matrix

Access 4 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is TGTX's Fair Value Range?

Spread across 7 independent models · $4.12 to $18.26

CirclFi's 7 active models place TG Therapeutics, Inc. (TGTX) between $4.12 and $18.26 per share, a spread of 119% of the median. The median of that range — $11.89 — is the fair value CirclFi publishes for TGTX, against a current price of $53.93.

Low · First ChicagoHigh · RCMH-DCF
$4.12median $11.89$18.26
Where the range comes from
Most bearish modelFirst Chicago$4.12
Most bullish modelRCMH-DCF$18.26
Model agreement0 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for TGTX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on TGTX, not a CirclFi price target. How each model works →

What Is TG Therapeutics, Inc. (TGTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, TG Therapeutics, Inc.'s intrinsic value is estimated at $11.89, suggesting the stock is overvalued at its current price of $53.93. With 7 out of 7 models flagging downside (-77.9% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About TGTX?

7 of 13 models are currently active for TGTX. All 7 active models suggest the stock trades above fair value. Taken together, their median fair value for TGTX is $11.89 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $11.89 on its own, implying -77.9% downside from the current price. See which stocks rank higher →

How Does TGTX Rank in Biotechnology?

Among 625 Biotechnology stocks, TGTX ranks #27 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places TGTX in the top tier.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, TG Therapeutics, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating TGTX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is TGTX a Value Trap?

CirclFi's Value Trap algorithm assigns TGTX a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for TG Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, TG Therapeutics, Inc.'s fundamental quality profile registers 8.1/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+26.2% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TGTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TGTX's 7 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy TG Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

KROSKeros Therapeutics, Inc.QOC 8.2VXRTVaxart, Inc.QOC 8.1TBPHTheravance Biopharma, Inc.QOC 8.2RPRXRoyalty Pharma plcQOC 8.1MNKDMannKind CorporationQOC 8.3LGNDLigand Pharmaceuticals IncorporatedQOC 7.9TRDAEntrada Therapeutics, Inc.QOC 5.7SRZNSurrozen, Inc.QOC 4.9ENVBEnveric Biosciences, Inc.QOC 4.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: KROS · VXRT · TBPH · RPRX · MNKD · LGND · TRDA · SRZN · ENVB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TGTX?

7 companies across all industries closest to TGTX’s Quality of Company score of 8.1/10.

NATLNCR Atleos CorporationQOC 8.1AXSAXIS Capital Holdings LimitedQOC 8.1VCIGVCI Global LimitedQOC 8.1HQIHireQuest, Inc.QOC 8.1JPMJPMorgan Chase & Co.QOC 8.1TKRThe Timken CompanyQOC 8.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NATL · AXS · VCIG · HQI · JPM · TKR · NVDA

Where Does TGTX Sit in CirclFi's Biotechnology Rankings?

TGTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About TG Therapeutics, Inc.’s Valuation?

What is TG Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts TG Therapeutics, Inc. (TGTX)'s intrinsic value at $11.89 — the median of 7 independent model estimates as of 2026-08-28, ranging from $4.12 to $18.26. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $11.89 on its own. The Quality of Company score is 8.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TGTX overvalued or undervalued right now?

At $53.93, 0 of 7 active models suggest TGTX may be undervalued, while 7 indicate potential overvaluation. The median of all 7 fair value estimates is $11.89, 77.9% below the current price of $53.93 — a consensus view that TGTX is overvalued. The assessment depends on which methodology best fits TG Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 8.1 mean for TGTX?

TG Therapeutics, Inc.'s QOC of 8.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on TGTX?

CirclFi analyzes TGTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TGTX?

Of the 7 models currently active on TGTX, RCMH-DCF is the most bullish at $18.26 per share, and First Chicago is the most bearish at $4.12. CirclFi's published fair value for TGTX is the median of that range, $11.89, not either extreme. The gap between the two ends equals 119% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is TGTX a value trap in 2026?

TG Therapeutics, Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, TG Therapeutics, Inc. (TGTX) has a median fair value of $11.89 — 77.9% below the current price of $53.93 — as of 2026-08-28.” Source: circlfi.com/stock/TGTX/ · Methodology
Primary sources for this TGTX valuation
  • Financial statements: TG Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001001316) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TGTX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on TGTX.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for TGTX Unlock All 7 — $39/mo